Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials

References

• SEER. Cancer stat facts. 2021; https://seer.cancer.gov/statfacts/more.html
   Google Scholar
• USCS. U.S. cancer statistics data visualizations tool, based on 2020 submission data (1999-2018). 2021; https://gis.cdc.gov/Cancer/USCS/#/AtAGlance/
   Google Scholar
• Bahena-González A, Toledo-Leyva A, Gallardo-Rincón D. PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies. Chin Clin Oncol. 2020;9(4):51.
   PubMed Web of Science ®Google Scholar
• Cortesi L, Rugo HS, Jackisch C. An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol. 2021;16(3):255–9.
   PubMed Web of Science ®Google Scholar
• Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol. 2015;33(12):1397–1406.
   PubMed Web of Science ®Google Scholar
• Du Y, Yamaguchi H, Hsu JL, et al. PARP inhibitors as precision medicine for cancer treatment. Natl Sci Rev. 2017;4(4):576–592.
   Web of Science ®Google Scholar
• Palleschi M, Tedaldi G, Sirico M, et al. Moving beyond PARP inhibition: current state and future perspectives in breast cancer. Int J Mol Sci. 2021;22(15):7884.
   PubMed Web of Science ®Google Scholar
• Rose M, Burgess JT, O’Byrne K, et al. PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol. 2020;8(879). DOI:10.3389/fcell.2020.564601
   PubMedGoogle Scholar
• Bartoletti M, Pelizzari G, Gerratana L, et al. Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: a network meta-analysis. Int J Mol Sci. 2020;21(11):3805.
   PubMed Web of Science ®Google Scholar
• Guy H, Walder L, Fisher M. Cost-effectiveness of niraparib versus routine surveillance, Olaparib and Rucaparib for the maintenance treatment of patients with ovarian cancer in the USA. PharmacoEconomics. 2019;37(3):391–405.
   PubMed Web of Science ®Google Scholar
• Guy H, Walder L, Fisher M. Response to ‘comment on “cost-effectiveness of Niraparib versus routine surveillance, Olaparib and rucaparib for the maintenance treatment of patients with ovarian cancer in the USA”’. PharmacoEconomics. 2019;37(7):965–967.
   PubMed Web of Science ®Google Scholar
• Wallace K, Goble S, Isaacson J, et al. Cost-effectiveness of niraparib versus routine surveillance, Olaparib and Rucaparib for the maintenance treatment of patients with ovarian cancer in the USA. PharmacoEconomics. 2019;37(8):1065–1067. Comment on.
   PubMed Web of Science ®Google Scholar
• Muston D, Hettle R, Monberg M, et al. Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the USA. Gynecol Oncol. 2020;159(2):491–497.
   PubMed Web of Science ®Google Scholar
• Brown JS, O’Carrigan B, Jackson SP, et al. Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discov. 2017;7(1):20–37.
   PubMed Web of Science ®Google Scholar
• Zhu H, Wei M, Xu J, et al. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Mol Cancer. 2020;19(1):49.
   PubMed Web of Science ®Google Scholar
• LaFargue CJ, Dal Molin GZ, Sood AK, et al. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20(1):e15–e28.
   PubMed Web of Science ®Google Scholar
• Madariaga A, Bowering V, Ahrari S, et al. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. International Journal of Gynecologic Cancer. 2020;30(7):903–915.
   PubMed Web of Science ®Google Scholar
• Wu L, Zhong L. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US. J Med Econ. 2019;22(2):187–195.
   PubMed Web of Science ®Google Scholar
• Zhong L, Tran AT, Tomasino T, et al. Cost-effectiveness of Niraparib and Olaparib as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer. J Manag Care Spec Pharm. 2018;24(12):1219–1228.
   PubMed Web of Science ®Google Scholar
• AHRQ. HCUPnet. 2017; https://hcupnet.ahrq.gov/#setup, 2021.
   Google Scholar
• Bureau of Labor Statistics. The economics daily, consumer price index: 2017 in review. 2018; https://www.bls.gov/opub/ted/2018/consumer-price-index-2017-in-review.htm?view_full, 2021.
   Google Scholar
• Bureau of Labor Statistics. The economics daily, consumer price index: 2020 in review. 2021; https://www.bls.gov/opub/ted/2021/consumer-price-index-2020-in-review.htm?view_full
   Google Scholar
• Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci. 1986;1(1):54–75.
   Google Scholar
• Jovanovic BD, Zalenski RJ. Safety evaluation and confidence intervals when the number of observed events is small or zero. Ann Emerg Med. 1997;30(3):301–306.
   PubMed Web of Science ®Google Scholar
• Bilir SP, Ma Q, Zhao Z, et al. Economic burden of toxicities associated with treating metastatic melanoma in the USA. Am Health Drug Benefits. 2016;9(4):203–213.
   PubMed Web of Science ®Google Scholar
• Wolford JE, Bai J, Eskander RH, et al. A Markov model to evaluate cost-effectiveness of the PARP inhibitor, olaparib, for fourth-line treatment of recurrent ovarian cancer. J Clin Oncol. 2016;34(15_suppl):5563.
   Web of Science ®Google Scholar
• Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416–2428.
   PubMed Web of Science ®Google Scholar
• Nooka AK. Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib. Oncology. 2013;27(3):11–18.
   PubMedGoogle Scholar
• Harvey RD. Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib. Clin Pharmacol. 2014;6:87–96.
   PubMedGoogle Scholar
• Colombo N, Moore K, Scambia G, et al. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. Gynecol Oncol. 2021;163(1):41–49.
   PubMed Web of Science ®Google Scholar
• Gallagher JR, Heap KJ, Carroll S, et al. Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study. Future Oncol. 2019;15(36):4197–4206.
   PubMed Web of Science ®Google Scholar
• Berek JS, Matulonis UA, Peen U, et al. Safety and dose modification for patients receiving niraparib. Ann Oncol. 2018;29(8):1784–1792.
   PubMed Web of Science ®Google Scholar
• Madariaga A, Bowering V, Ahrari S, et al. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. Int J Gynecologic Cancer. 2020;30(7):903–915.
   PubMed Web of Science ®Google Scholar
• McCrea C, Hettle R, Gulati P, et al. Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer. J Comp Eff Res. 2021;10(13):1021–1030.
   PubMed Web of Science ®Google Scholar
• Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–2505.
   PubMed Web of Science ®Google Scholar
• González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–2402.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–1284.
   PubMed Web of Science ®Google Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–2164.
   PubMed Web of Science ®Google Scholar
• Coleman R, Oza A, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–1961.
   PubMed Web of Science ®Google Scholar
• Robson M, S-A I, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–533.
   PubMed Web of Science ®Google Scholar
• Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753–763.
   PubMed Web of Science ®Google Scholar